Approval · Notice of Compliance 843 · 2002
TAZORAC: Notice of Compliance 843
Issued May 15, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 843
- Date
- May 15, 2002
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for the topical treatment of acne vulgaris
- Therapeutic class
- Anti-psoriasis agent, anti-acne agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TAZORAC | Not yet assigned | — |
Medicinal ingredients
- TAZAROTENE 0.1 PER